* Expecting agreements to materialise * Costs still in check * We keep our fair value to SEK 4.23 per share In the Q1 report 2025, CEO Edvard Hall updated on current projects. Before the Q2 report in August, we expect some of the collaborations to advance...
* Several agreements approaching * Costs in line with expectations * We have adjusted our fair value to SEK 4.23 per share The reported figures in Bioextrax's recent Q4 report were close to our estimates. With no significant sales forecast, costs came...
* High interest amid progression of the projects * The rights issue in Q4 added MSEK 14.1 * We keep our fair value of SEK 7.60 per share Bioextrax has received numerous inquiries from research institutes and companies since the summer. At the same time...
[ingress] * Letter of intent with a leading chemical company * License agreement with Chematur Engineering regarding PHBV * We keep our fair value of SEK 7.60 per share During Q2, Bioextrax's project advanced. The company has entered into a license agreement...
* Ökat fokus på affärsutveckling * En övertecknad emission gav 9 MSEK * Vi behåller det motiverade värdet om 7,60 SEK per aktie Under 2024 kommer Bioextrax att visa sin förmåga att omvandla lovande projekt till kommersiella avtal. Bolaget uppdaterade...
Västra Hamnen besöker Bioextrax i Lund och diskuterar vad som har hänt det senaste året samt pågående företrädesemission.
* Joint Development Agreement with the candy producer in Q1 * Progression in several projects, funding risk remains * Our model implies a fair valuation of SEK 7.60 per share A quiet final quarter of 2023 was followed by an eventful start of 2024 for...
* Limited effect on short-term earnings, higher perceived risk * Bioextrax signs MoU with Chematur Engineering * We have adjusted the fair value to SEK 7.60 (10.50) per share In September 2023, an American start-up company extended the license agreement...
* EU proposes measures targeting microplastic pollution * Enhanced cost control * Our model implies a fair valuation of SEK 10.5 per share During the third quarter, Bioextrax reached a commercial milestone when the American licensee exercised its option...
* American start-up company exercises option for the next period * Warrants subscription adds SEK 10.6 million before issue costs * Our model implies a fair valuation of SEK 10.5 per share Bioextrax shows continued progress in its Q2 report for 2023....
* Scale-up facility is expected to be fully operational in Q2 2023 * Signing MOU and binding term sheet with new partners * Our model implies a fair valuation of SEK 10.5 per share In the first quarter of 2023, Bioextrax reported stronger revenues and...
* Solutions enabling production of bio-based and biodegradable plastics * Licencing revenue model enabling fast scalability and operating leverage * We initiate coverage with a fair value of SEK 10.5 per share Bioextrax has developed a unique process...